To improve the safety of plasma derived factor VIII (FVIII) concentrate, we introduced a final super heat treatment (100° C for 30 min) as additional virus inactivation step applied to a lyophilized, highly purified FVIII concentrate (100 IU/mg of proteins) already virus inactivated using the solvent/detergent (SID) method during the manufacturing process.
The efficiency of the super heat treatment was demonstrated in inactivating two non-lipid enveloped viruses (Hepatitis A virus and Poliovirus 1). The loss of FVIII procoagulant activity during the super heat treatment was of about 15%, estimated both by clotting and chromogenic assays. No substantial changes were observed in physical, biochemical and immunological characteristics of the heat treated FVIII concentrate in comparison with those of the FVIII before heat treatment.
References
1
Peerlink K,
Vermylen J.
Acute Hepatitis A in patients with haemophilia A. Lancet 1993; 341: 179
2
Mannucci PM,
Gdovin S,
Gringeri A,
Colombo M,
Mele A,
Schinaia N,
Ciavarella N,
Emerson SU,
Purcell RH.
Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120 (01) 1-7
3
Morfini M,
Mannucci PM,
Ciavarella N,
Schiavoni M.
Prevalence of infection with the Hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang 1994; 67: 178-182
7
Schimpf K,
Brackmann HH,
Kreuz W,
Kraus B,
Haschke F,
Scftritmm W,
Moessler J,
Auerswald G,
Sutor AH,
Koehler K,
Hellstern P,
Muntean W,
Scharrer I.
Absence of antihuman immunodeficiency virus types 1 and 2 seroconversion after treatment with hemophilia A and B or von Wille-brand’s disease with pasteurized factor concentrate. N Engl J Med 1989; 321: 1148-1152
8
Mannucci PM,
Schimpf K,
Brettler DB,
Ciavarella N,
Colombo M,
Haschke F,
Lechner K,
Lusher J,
Weissbach G.
the International Study Group. Low risk for Hepatitis in hemophiliacs given a high purity, pasteurized factor VIII concentrate Ann Intern Med 1990; 113: 27-32
10
Skidmore SJ,
Pasi KJ,
Mawson SJ,
Williams MD,
Hill FG H.
Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-U Hepatitis. J Med Virol 1990; 30: 50-52
11
Rizza CR,
Fletcher ML,
Kernoff PBA.
Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory: A report on behalf of UK Haemophilia Centre Directors. Br J Haematol 1993; 84: 269-272
12
Mariani G,
Di Paoloantonio T,
Baklaya R,
Morfini M,
Mannucci PM.
Ad Hoc Study Group of the Fondazione Dell’Emofilia. Prospective study of the evaluation of Hepatitis C virus infectivity in a high purity, solvent/ detergent-treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses Transfusion 1993; 33: 814-818
15
Bartolomei CorsiO,
Azzi A,
Morfini M,
Fauci R,
Rossi Ferrini P.
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrate. J Med Virol 1988; 25: 165-170
17
Azzi A,
Ciappi S,
Zakvzeswska K,
Morfini M,
Mariani G,
Mannucci PM.
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity virally attenuated factor VIII concentrates. J Hematol 1992; 39: 228-230
18
Grobe-Bley A,
Eis-Hübinger AM,
Kaiser R,
Oldenburg J,
Brackmann HH,
Schwarz TF,
Schneweis KE.
Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost 1994; 72: 503-507
21
Rubinstein AI,
Rubinstein DB,
Coughlin J.
Combined solvent-detergent and 100° C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility. Vox Sang 1991; 60: 60
22
Franco E,
Divizia M,
De Santis ME,
Arrighi S,
Borri MG.
Inattivazione tramite calore secco del Poliovirus 1 in campioni di fattore VIII. 35th National Congress of Italian Society of Hygene (Std), Montecatini Terme. Italy: 1992: 180-183
23
Jansen RW,
Siegl G,
Lemon SM.
Molecular epidemiology of human Hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proe Natl Acad Sci USA 1990; 87: 2867-2871
24
Morace G,
Pisani G,
Divizia M,
Paná A.
Detection of Hepatitis A virus in concentrated river water by Polymerase chain reaction. Zentralblatt für Hygiene und Umweltmedizin 1993; 193: 521-527
26
Hubbard AR,
Curtis AD,
Barrowelilfe TV,
Edwards SJ,
Jennings CA,
Kemball-Cook G.
Assay of factor VIII concentrates: comparison of the chromogenic and two stage clotting assay. Thromb Res 1986; 44: 887-891
29
Towbin H,
Staehelin T,
Gordon J.
Electrophoretic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 1970; 76: 1350-1354
30
Grabar P,
Williams CA.
Métode permettante l’etude conjugée des propriété électrophoréiques et immunochimiqués d’une mélange de proteines: application au sérum sanguin. Biochim Biophys Acta (Amst) 1953; 10: 193
32
Nencioni L,
Villa L,
Tagliabue A,
Antoni G,
Presentini R,
Perin F,
Silvestri S,
Boraschi D.
In vivo immunostimulating activity of the 163-171 peptide of human IL-1ß. J Immunol 1987; 139: 800-804
34
Sanchez-Cuenca JM,
Carmona E,
Villanueva MJ,
Aznar JA.
Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990; 57: 897-908
